These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 32538994)

  • 1. Antibody-drug conjugates: the new generation of biotechnological therapies against cancer.
    Melgarejo-Rubio G; Pérez-Tapia SM; Medina-Rivero E; Velasco-Velázquez MA
    Gac Med Mex; 2020; 156(3):228-235. PubMed ID: 32538994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antibody-drug conjugates: a new therapeutic class?].
    Chofflon I; Dietrich PY; Thang NN
    Rev Med Suisse; 2013 May; 9(387):1080-2, 1084-6. PubMed ID: 23757915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy.
    Jerjian TV; Glode AE; Thompson LA; O'Bryant CL
    Pharmacotherapy; 2016 Jan; 36(1):99-116. PubMed ID: 26799352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies and challenges for the next generation of antibody-drug conjugates.
    Beck A; Goetsch L; Dumontet C; Corvaïa N
    Nat Rev Drug Discov; 2017 May; 16(5):315-337. PubMed ID: 28303026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): the experience of gemtuzumab ozogamicin.
    Cianfriglia M
    Ann Ist Super Sanita; 2013; 49(2):150-68. PubMed ID: 23771260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes.
    Abdollahpour-Alitappeh M; Lotfinia M; Gharibi T; Mardaneh J; Farhadihosseinabadi B; Larki P; Faghfourian B; Sepehr KS; Abbaszadeh-Goudarzi K; Abbaszadeh-Goudarzi G; Johari B; Zali MR; Bagheri N
    J Cell Physiol; 2019 May; 234(5):5628-5642. PubMed ID: 30478951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-Drug Conjugates: Pharmacokinetic/Pharmacodynamic Modeling, Preclinical Characterization, Clinical Studies, and Lessons Learned.
    Hedrich WD; Fandy TE; Ashour HM; Wang H; Hassan HE
    Clin Pharmacokinet; 2018 Jun; 57(6):687-703. PubMed ID: 29188435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma.
    Yu B; Liu D
    J Hematol Oncol; 2019 Sep; 12(1):94. PubMed ID: 31500657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting system.
    Lin W; Xu J; Liao Y; Lin X; Yang J; Zhuang W
    Int J Clin Pharm; 2024 Jun; 46(3):614-622. PubMed ID: 38100054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-drug conjugate technology development for hematologic disorders.
    Bander NH; Czuczman MS; Younes A
    Clin Adv Hematol Oncol; 2012 Aug; 10(8 Suppl 10):1-16. PubMed ID: 23072775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining Biology and Chemistry for a New Take on Chemotherapy: Antibody-Drug Conjugates in Hematologic Malignancies.
    Ma H; Sawas A
    Curr Hematol Malig Rep; 2018 Dec; 13(6):555-569. PubMed ID: 30362019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigational Antibody-Drug Conjugates for Treatment of B-lineage Malignancies.
    Herrera AF; Molina A
    Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):452-468.e4. PubMed ID: 29804872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. World Antibody Drug Conjugate Summit Europe: February 21-23, 2011; Frankfurt, Germany.
    Beck A; Senter P; Chari R
    MAbs; 2011; 3(4):331-7. PubMed ID: 21691144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-drug conjugates in cancer therapy.
    Sievers EL; Senter PD
    Annu Rev Med; 2013; 64():15-29. PubMed ID: 23043493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-drug conjugates for cancer therapy.
    Thomas A; Teicher BA; Hassan R
    Lancet Oncol; 2016 Jun; 17(6):e254-e262. PubMed ID: 27299281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-drug conjugates in tumor therapy.
    Sammet B; Steinkühler C; Sewald N
    Pharm Pat Anal; 2012 Mar; 1(1):65-73. PubMed ID: 24236714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linked-in: design and efficacy of antibody drug conjugates in oncology.
    Feld J; Barta SK; Schinke C; Braunschweig I; Zhou Y; Verma AK
    Oncotarget; 2013 Mar; 4(3):397-412. PubMed ID: 23651630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-targeted drugs and drug resistance--challenges and solutions.
    Shefet-Carasso L; Benhar I
    Drug Resist Updat; 2015 Jan; 18():36-46. PubMed ID: 25476546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates.
    Jackson D; Stover D
    Pharm Res; 2015 Nov; 32(11):3458-69. PubMed ID: 25339341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour-targeted chemotherapy with immunoconjugates of calicheamicin.
    Damle NK
    Expert Opin Biol Ther; 2004 Sep; 4(9):1445-52. PubMed ID: 15335312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.